The latest market report published by Credence Research, Inc. the global donor egg IVF treatment market was valued at US$1,782.1 million in 2018 and is expected to reach US$3,676.8 million by 2027, expanding at a CAGR of 8.4% from 2019 to 2027.Donor Egg IVF Treatment Market 2019-2027 originaly published on credenceresearch.com
Market Insights Donor egg IVF treatment involves recovering healthy viable eggs from donors below 33 years of age and fertilizing with in vitro sperm in fertility clinics. The embryo is then placed in the womb of the recipient. The procedure can be performed in elderly women with early menopause, endometriosis, tuberculosis, etc. Significant increase in fertility tourism and rampant growth in egg cryopreservation banks to give the donor egg IVF treatment market growth the necessary impetus.
Fresh donor egg IVF cycle type dominates the market. The primary reasons associated with its overwhelming popularity among clients are high success rate associated with pregnancy and efficient method of retrieving highly viable embryos. The limitation associated with the cycle of fresh donor egg IVF is the long waiting period. Frozen donor egg IVF cycle is gaining huge traction due to effective egg screening, consistent cohorts ready to be shipped, thawed and ready to be used as per customer schedule. Late marriages, surrogacy and family planning motivate people to freeze future children’s eggs.
The end-user segment of donor egg IVF treatment market reigns in fertility clinics. The inherent features such as technological advancement in IVF techniques such as egg freezing, hatching, vitrification, gamete intrafallopian transfer (GIFT) etc. provide the necessary thrust for market growth in fertility clinics. Government healthcare agencies around the world are providing huge financial assistance to establish hospital IVF treatment centers for catering clients residing in remote locations.
North America currently has a market share of 34 percent and is the largest regional donor egg IVF treatment market. The primary factors contributing to its splendid growth are increasing the prevalence of early menopause and increasing public health awareness of infertility. Europe holds 32 percent market share in the future due to the paradigm shift observed in social life, with a significant increase in working women, late marriages and family planning for children and siblings. Asia Pacific currently holds 24 percent due to the increase in fertility tourism and rampant growth in the number of fertility clinics well equipped with sophisticated IVF treatment techniques and equipment.
Pharmaceutical companies specializing in providing IVF treatment services are Cook Medical, Inc., EMD Serono, Inc., Flinders Reproductive Medicine Pty. Ltd., Fertility First, Genea Oxford Fertility Limited, OvaScience, Procrea Fertility, Progyny, Inc., ReproMed and Vitrolife AB.
Get Sample Brochure in PDF: https://www.credenceresearch.com/sample-request/59701